This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Hoffmann-La Roche Inc.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Tobias Nilsson: Innovator in Antisense Oligonucleotide Technology
Introduction
Tobias Nilsson is a prominent inventor based in Basel, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of antisense oligonucleotides. His work focuses on innovative solutions for treating viral infections, showcasing his commitment to advancing medical science.
Latest Patents
Tobias Nilsson holds a patent for "Enhanced oligonucleotides for inhibiting RTEL1 expression." This patent provides antisense oligonucleotides that target the Regulator of telomere elongation helicase 1 (RTEL1). The invention aims to treat and prevent hepatitis B virus (HBV) infections through enhanced antisense oligonucleotides. Additionally, the patent includes pharmaceutical compositions and their applications.
Career Highlights
Tobias Nilsson is associated with Hoffmann-La Roche Inc., a leading global healthcare company. His role at the company allows him to collaborate with other experts in the field and contribute to groundbreaking research and development.
Collaborations
Tobias has worked alongside notable colleagues, including Erik Daa Funder and Natascha Hruschka. Their collaborative efforts have furthered the research and development of innovative therapeutic solutions.
Conclusion
Tobias Nilsson's work in the field of antisense oligonucleotides represents a significant advancement in the treatment of viral infections. His innovative approach and dedication to research continue to impact the biotechnology landscape positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile